Biotech upstarts test new biz models to provide returns

Xconomy's Luke Timmerman has a column today that is provocatively called "How to make money in biotech with no hope of going public, slim odds of getting acquired." Indeed, biotech start-ups have adopted corporate structures that offer investors returns without the firms completing IPOs or being acquired by Big Pharma companies. Timmerman points to Seattle-based Resolve Therapeutics, which was organized as a limited liability company to offer returns to investors if the firm lands a licensing deal with another company. We've also seen this LLC model adopted at Cambridge, MA-based Nimbus Discovery, whose interesting virtual drug discovery strategy I covered for my column in FierceBiotech IT last week. Article

Suggested Articles

NASH leaders weigh in on the need for a drug for the disease and the challenges in getting it to patients.

The $210 million fund began life by leading a $17 million series A round in Quellis Biosciences.

The nine-story building will house Amgen’s Bay Area employees when it opens early in 2022.